Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mesothelioma

- PMLiVE

BMS partners with Voluntis to co-develop oncology digital therapeutics

Aims to create a mobile app to help patients self-manage their symptoms

- PMLiVE

BMS scores first oesophageal cancer nod for Opdivo in Japan

Approval in Japan comes before US okay

- PMLiVE

Immutep spikes on trial of its LAG-3 drug with Keytruda

Impressive mid-stage results in NSCLC and HNSCC

- PMLiVE

Bluebird bio leans on pipeline and Zynteglo launch as revenues fall

Revenues down from last year but beat analyst expectations

- PMLiVE

BMS’ Opdivo combo misses the mark in pancreatic cancer

Failed to reach primary endpoint of progression-free survial

- PMLiVE

Merck’s Ebola vaccine wins approval in four African countries

Follows approvals in US and Europe last year

- PMLiVE

BMS unveils long-term results for Opdivo in kidney cancer

Results include updated data for Opdivo with or without Yervoy

- PMLiVE

FDA begins speedy review of BMS’ CAR-T liso-cel

Agency sets target action date of 17 August for final decision

- PMLiVE

Merck chases Roche with triple-negative breast cancer data for Keytruda

Data demonstrated a delay in disease progression or death

- PMLiVE

NICE turns down Keytruda/Inlyta combo for kidney cancer

Cost-effectiveness agency says the long-term benefit is uncertain

- PMLiVE

Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

BMS share price up by 3% on the back of results

- PMLiVE

Merck spins off low-growth drugs in a ‘purposeful shift’ of focus

Fourth quarter results overshadowed by spin off announcement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links